subgroup of
drug)
→
CapableOf
→
receive fda approval
| Typicality: | 0.515 |
| Saliency: | 0.241 |
| in 2011 | 3 | temporal |
| to treat advanced melanoma | 2 | purpose |
| new drug → receive → fda approval | 5 |
| new drug → gain → fda approval | 3 |
| negative | neutral | positive |
| 0.110 | 0.542 | 0.348 |
| Raw frequency | 8 |
| Normalized frequency | 0.241 |
| Modifier score | 1.000 |
| Perplexity | 147.561 |